Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under
https://medium.com/@mingchikuo/dells-total-server-shipments-are-expected-to-return-to-significnat-growth-of-about-15-yoy-in-2024-d40c85c3a57f My latest supply chain check indicates that the higher-than-expected